Back to Results

Argenx NV ADR (ARGX)

Featured in Rapid Revenue Growth

argenx NV ADR is a depositary receipt listed on NASDAQ that represents common stock of argenx SE, a commercial-stage biopharma company focused on therapies for autoimmune and other immune-mediated diseases. The company markets VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and VYVGART HYTRULO for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its development pipeline includes efgartigimod, empasiprubart, adimanebart, and several earlier-stage programs such as ARGX-213, ARGX-124, ARGX-109, ARGX-121, ARGX-118, cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. argenx also maintains strategic partnerships and license agreements with Zai Lab, Halozyme Therapeutics, OncoVerity, and AbbVie. The company was incorporated in 2008 and is based in Amsterdam, the Netherlands.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-ARGX
$922.01
5.9% Upside
Fair
$1,055
21.2% Upside
Undervalued
Great
—
—
—
0.0%
July 23, 2026
36.5x
7.4x
11.4x
53.85 B
49.942 B
0.1%
99.8%
—
—
45.6%
Send a message
Valuation • Fair Value

argenx NV ADR (NASDAQ-ARGX) Fair Value by Valuation Model

Compare the primary fair value estimate for argenx NV ADR (NASDAQ-ARGX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$922.01

Estimated upside of 5.9% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$1,025

Discounted cash flow valuation reference.

Ben Graham Formula Value

$264.09

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$819.27

Comparable-company valuation reference.

Analyst Price Target

$1,055

Analysts imply upside of 21.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for argenx NV ADR (NASDAQ-ARGX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for argenx NV ADR (NASDAQ-ARGX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

4.742 B

Current operating scale indicator.

Revenue Forecast

6.021 B

Forward revenue estimate.

EBITDA

1.318 B

Current operating profitability reference.

EBITDA Forecast

1.911 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review argenx NV ADR (NASDAQ-ARGX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for argenx NV ADR (NASDAQ-ARGX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

45.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for argenx NV ADR (NASDAQ-ARGX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for argenx NV ADR (NASDAQ-ARGX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 23, 2026

Days to Earnings

2

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for argenx NV ADR (NASDAQ-ARGX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

argenx NV ADR (NASDAQ-ARGX) Stock Forecast & Technical Outlook

Review argenx NV ADR (NASDAQ-ARGX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for argenx NV ADR (NASDAQ-ARGX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for argenx NV ADR (NASDAQ-ARGX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for argenx NV ADR (NASDAQ-ARGX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for argenx NV ADR (NASDAQ-ARGX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for argenx NV ADR (NASDAQ-ARGX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for argenx NV ADR (NASDAQ-ARGX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, argenx NV ADR (NASDAQ-ARGX) has a Strong Buy consensus, with 15 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 15
Hold 3
Sell 0
FAQ • Fast Investor Answers

argenx NV ADR (NASDAQ-ARGX) Stock FAQ

Quick answers about argenx NV ADR (NASDAQ-ARGX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$922.01
Estimated upside 5.9%
Valuation Rating
Undervalued
Estimated upside of 5.9%
Analyst Target
$1,055
Implied upside 21.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for argenx NV ADR (NASDAQ-ARGX) is $922.01. This implies an estimated upside of 5.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.9% versus the current market price.

The available analyst price target for argenx NV ADR (NASDAQ-ARGX) is $1,055. The analyst target implies estimated upside of 21.2%.

The current financial health read for argenx NV ADR (NASDAQ-ARGX) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for argenx NV ADR (NASDAQ-ARGX) is July 23, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for argenx NV ADR (NASDAQ-ARGX) is 36.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for argenx NV ADR is 53.85 B.

The current enterprise value listed for argenx NV ADR is 49.942 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for argenx NV ADR is NASDAQ-ARGX, and the stock is listed on NASDAQ.

argenx NV ADR (NASDAQ-ARGX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for argenx NV ADR is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for argenx NV ADR is 99.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)
Cytokinetics Inc (CYTK) Cytokinetics Inc (CYTK)